Karyopharm Therapeutics Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022. Based on preliminary unaudited financial information, the company expects total revenue, which includes license and royalty revenue from partners, to be approximately $34.2 million for the fourth quarter 2022 and net product revenue for XPOVIO in the U.S. to be approximately $31.1 million for the fourth quarter 2022.
Based on preliminary unaudited financial information, the company expects total revenue, which includes license and royalty revenue from partners, to be approximately $157.7 million for the full year 2022 and net product revenue for XPOVIO in the U.S. to be approximately $120.4 million for the full year 2022, representing growth of 22% over 2021.